Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:21 PM
Ignite Modification Date:
2025-12-24 @ 7:21 PM
NCT ID:
NCT00403403
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease
* Measurable disease or lesions
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
* Life expectancy of \< 12 weeks
* Current, recent, or planned participation in another experimental drug study
* Ongoing or active infection
* Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years
* Prior systemic therapy, radiation therapy, or surgery for SCLC
* Inadequate bone marrow function, renal function, or hepatic function
* Serum sodium of \< 120 mg/dL
* Inadequately controlled hypertension
* History of hypertensive crisis or hypertensive encephalopathy
* New York Heart Association Class II or greater congestive heart failure
* History of myocardial infarction or unstable angina within 6 months prior to study enrollment
* History of stroke or transient ischemic attack within 6 months prior to study enrollment
* Known central nervous system disease, except for brain metastases treated with whole-brain radiotherapy
* Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment
* History of hemoptysis within 4 weeks prior to study enrollment
* Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study
* Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1
* History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment
* Serious, non-healing wound, active ulcer, or untreated bone fracture
* Known hypersensitivity to any component of bevacizumab
* Pregnant (positive pregnancy test) or lactating
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00403403
Study Brief:
Protocol Section:
NCT00403403